These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

527 related articles for article (PubMed ID: 25769911)

  • 41. Psoriatic skin molecular and histopathologic profiles after treatment with risankizumab versus ustekinumab.
    Visvanathan S; Baum P; Vinisko R; Schmid R; Flack M; Lalovic B; Kleiner O; Fuentes-Duculan J; Garcet S; Davis JW; Grebe KM; Fine JS; Padula SJ; Krueger JG
    J Allergy Clin Immunol; 2019 Jun; 143(6):2158-2169. PubMed ID: 30578873
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Efalizumab for patients with moderate to severe plaque psoriasis: a randomized controlled trial.
    Gordon KB; Papp KA; Hamilton TK; Walicke PA; Dummer W; Li N; Bresnahan BW; Menter A;
    JAMA; 2003 Dec; 290(23):3073-80. PubMed ID: 14679270
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Efficacy and safety of ustekinumab in Japanese patients with moderate-to-severe plaque-type psoriasis: long-term results from a phase 2/3 clinical trial.
    Igarashi A; Kato T; Kato M; Song M; Nakagawa H;
    J Dermatol; 2012 Mar; 39(3):242-52. PubMed ID: 21955098
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Novel biologic therapies in development targeting IL-12/IL-23.
    van de Kerkhof PC
    J Eur Acad Dermatol Venereol; 2010 Oct; 24 Suppl 6():5-9. PubMed ID: 20831703
    [TBL] [Abstract][Full Text] [Related]  

  • 45. CLinical experience acquired with the efalizumab (Raptiva) (CLEAR) trial in patients with moderate-to-severe plaque psoriasis: results from a phase III international randomized, placebo-controlled trial.
    Dubertret L; Sterry W; Bos JD; Chimenti S; Shumack S; Larsen CG; Shear NH; Papp KA;
    Br J Dermatol; 2006 Jul; 155(1):170-81. PubMed ID: 16792770
    [TBL] [Abstract][Full Text] [Related]  

  • 46. IL-17A inhibition by secukinumab induces early clinical, histopathologic, and molecular resolution of psoriasis.
    Krueger JG; Wharton KA; Schlitt T; Suprun M; Torene RI; Jiang X; Wang CQ; Fuentes-Duculan J; Hartmann N; Peters T; Koroleva I; Hillenbrand R; Letzkus M; Yu X; Li Y; Glueck A; Hasselberg A; Flannery B; Suárez-Fariñas M; Hueber W
    J Allergy Clin Immunol; 2019 Sep; 144(3):750-763. PubMed ID: 31129129
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Short-term transcriptional response to IL-17 receptor-A antagonism in the treatment of psoriasis.
    Tomalin LE; Russell CB; Garcet S; Ewald DA; Klekotka P; Nirula A; Norsgaard H; Suàrez-Fariñas M; Krueger JG
    J Allergy Clin Immunol; 2020 Mar; 145(3):922-932. PubMed ID: 31883845
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials.
    Reich K; Papp KA; Blauvelt A; Tyring SK; Sinclair R; Thaçi D; Nograles K; Mehta A; Cichanowitz N; Li Q; Liu K; La Rosa C; Green S; Kimball AB
    Lancet; 2017 Jul; 390(10091):276-288. PubMed ID: 28596043
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A Phase 2 Trial of Guselkumab versus Adalimumab for Plaque Psoriasis.
    Gordon KB; Duffin KC; Bissonnette R; Prinz JC; Wasfi Y; Li S; Shen YK; Szapary P; Randazzo B; Reich K
    N Engl J Med; 2015 Jul; 373(2):136-44. PubMed ID: 26154787
    [TBL] [Abstract][Full Text] [Related]  

  • 50. IMO-8400, a toll-like receptor 7, 8, and 9 antagonist, demonstrates clinical activity in a phase 2a, randomized, placebo-controlled trial in patients with moderate-to-severe plaque psoriasis.
    Balak DM; van Doorn MB; Arbeit RD; Rijneveld R; Klaassen E; Sullivan T; Brevard J; Thio HB; Prens EP; Burggraaf J; Rissmann R
    Clin Immunol; 2017 Jan; 174():63-72. PubMed ID: 27876460
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A review article on brodalumab in the treatment of moderate-to-severe plaque psoriasis.
    Roostaeyan O; Kivelevitch D; Menter A
    Immunotherapy; 2017 Sep; 9(12):963-978. PubMed ID: 28879789
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Safety of efalizumab in adults with chronic moderate to severe plaque psoriasis: a phase IIIb, randomized, controlled trial.
    Papp KA; Bressinck R; Fretzin S; Goffe B; Kempers S; Gordon KB; Caro I; Walicke PA; Wang X; Menter A;
    Int J Dermatol; 2006 May; 45(5):605-14. PubMed ID: 16700803
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Psoriasis: from Pathogenesis to Targeted Therapies.
    Conrad C; Gilliet M
    Clin Rev Allergy Immunol; 2018 Feb; 54(1):102-113. PubMed ID: 29349534
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Efficacy and safety results from a phase III, randomized controlled trial comparing the safety and efficacy of briakinumab with etanercept and placebo in patients with moderate to severe chronic plaque psoriasis.
    Strober BE; Crowley JJ; Yamauchi PS; Olds M; Williams DA
    Br J Dermatol; 2011 Sep; 165(3):661-8. PubMed ID: 21574984
    [TBL] [Abstract][Full Text] [Related]  

  • 55. IL-17A is essential for cell activation and inflammatory gene circuits in subjects with psoriasis.
    Krueger JG; Fretzin S; Suárez-Fariñas M; Haslett PA; Phipps KM; Cameron GS; McColm J; Katcherian A; Cueto I; White T; Banerjee S; Hoffman RW
    J Allergy Clin Immunol; 2012 Jul; 130(1):145-54.e9. PubMed ID: 22677045
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Safety of tildrakizumab for moderate-to-severe plaque psoriasis: pooled analysis of three randomized controlled trials.
    Blauvelt A; Reich K; Papp KA; Kimball AB; Gooderham M; Tyring SK; Sinclair R; Thaçi D; Li Q; Cichanowitz N; Green S; La Rosa C
    Br J Dermatol; 2018 Sep; 179(3):615-622. PubMed ID: 29742274
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The treatment of moderate to severe psoriasis with a new anti-CD11a monoclonal antibody.
    Papp K; Bissonnette R; Krueger JG; Carey W; Gratton D; Gulliver WP; Lui H; Lynde CW; Magee A; Minier D; Ouellet JP; Patel P; Shapiro J; Shear NH; Kramer S; Walicke P; Bauer R; Dedrick RL; Kim SS; White M; Garovoy MR
    J Am Acad Dermatol; 2001 Nov; 45(5):665-74. PubMed ID: 11606914
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Therapeutic benefit of blocking interleukin-6 activity with an anti-interleukin-6 receptor monoclonal antibody in rheumatoid arthritis: a randomized, double-blind, placebo-controlled, dose-escalation trial.
    Choy EH; Isenberg DA; Garrood T; Farrow S; Ioannou Y; Bird H; Cheung N; Williams B; Hazleman B; Price R; Yoshizaki K; Nishimoto N; Kishimoto T; Panayi GS
    Arthritis Rheum; 2002 Dec; 46(12):3143-50. PubMed ID: 12483717
    [TBL] [Abstract][Full Text] [Related]  

  • 59. HSP90 inhibitor RGRN-305 for oral treatment of plaque-type psoriasis: efficacy, safety and biomarker results in an open-label proof-of-concept study.
    Bregnhøj A; Thuesen KKH; Emmanuel T; Litman T; Grek CL; Ghatnekar GS; Johansen C; Iversen L
    Br J Dermatol; 2022 May; 186(5):861-874. PubMed ID: 34748646
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Anti-interleukin-17 monoclonal antibody ixekizumab in chronic plaque psoriasis.
    Leonardi C; Matheson R; Zachariae C; Cameron G; Li L; Edson-Heredia E; Braun D; Banerjee S
    N Engl J Med; 2012 Mar; 366(13):1190-9. PubMed ID: 22455413
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 27.